Abstract |
The dual phosphatases CDC25 are involved in cell cycle regulation and overexpressed in many tumours, including melanoma. CDC25 is a promising target for discovering anticancer drugs, and several studies focussed on characterisation of quinonoid CDC25 inhibitors, frequently causing undesired side toxic effects. Previous work described an optimisation of the inhibition properties by naphthylphenylamine (NPA) derivatives of NSC28620, a nonquinonoid CDC25 inhibitor. Now, the CDC25B•inhibitor interaction was investigated through fluorescence studies, shedding light on the different inhibition mechanism exerted by NPA derivatives. Among the molecular processes, mediating the specific and high cytotoxicity of one NPA derivative in melanoma cells, we observed decrease of phosphoAkt, increase of p53, reduction of CDC25 forms, cytochrome c cytosolic translocation and increase of caspase activity, that lead to the activation of an apoptotic programme. A basic knowledge on CDC25 inhibitors is relevant for discovering potent bioactive molecules, to be used as anticancer agents against the highly aggressive melanoma.
|
Authors | Federica Aliotta, Rosarita Nasso, Rosario Rullo, Alessandro Arcucci, Angelica Avagliano, Martina Simonetti, Gennaro Sanità, Mariorosario Masullo, Antonio Lavecchia, Maria Rosaria Ruocco, Emmanuele De Vendittis |
Journal | Journal of enzyme inhibition and medicinal chemistry
(J Enzyme Inhib Med Chem)
Vol. 35
Issue 1
Pg. 1866-1878
(Dec 2020)
ISSN: 1475-6374 [Electronic] England |
PMID | 32990107
(Publication Type: Journal Article)
|
Chemical References |
- Aniline Compounds
- Antineoplastic Agents
- Enzyme Inhibitors
- cdc25 Phosphatases
- Caspase 3
- Caspase 9
|
Topics |
- Amino Acid Sequence
- Aniline Compounds
(chemistry)
- Antineoplastic Agents
(chemistry, pharmacology)
- Apoptosis
(drug effects)
- Caspase 3
(metabolism)
- Caspase 9
(metabolism)
- Catalytic Domain
- Cell Line, Tumor
- Drug Screening Assays, Antitumor
- Enzyme Inhibitors
(chemistry, pharmacology)
- Humans
- Melanoma
(drug therapy)
- Mutation
- Optical Imaging
- Structure-Activity Relationship
- cdc25 Phosphatases
(antagonists & inhibitors)
|